Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...

Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to ...

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...

After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.  | ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

U.S. pharmaceutical lobby group PhRMA has launched a new ad offensive that looks to highlight the American life sciences ...

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to ...

In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to ...

Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...

With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break ...